Cart is empty
RayBiotech News Releases
September 11, 2013 - Norcross, GA
RayBiotech, Inc. announced today that the company has been awarded ISO 13485: 2003 certification with respect to its compliance in the manufacture of in vitro diagnostics kits to be provided to the research community. The ISO 13485 award applies to multivariant antibody arrays, enzyme-linked immunosorbent assays (ELISAs) as well as membrane and glass format arrays and reagents. ISO 13485 is the International Organization for Standardization's certification that the fundamentals of quality management are in place and actively implemented as formal systems within the organization. The ISO 13485 compliance certification is in addition to the company's formal compliance under Good Laboratory Practices (GLP) and... more....
April 3, 2013 - Norcross, GA
RayBiotech, Inc. announced today that the application of its Mouse Cytokine Antibody Array has enabled the identification of key factors involved in the dissemination of leprosy infection in humans. This seminal research was conducted by Dr. Anura Rambukkana and colleagues at the Medical Research Council Center for Regenerative Medicine, University of Edinburgh and the Rockefeller University in New York. In this study, Dr. Rambukkana's team employed RayBiotech's Mouse Cytokine Antibody Array C-Series 1000 to test for the presence of biologically active proteins in media conditioned by adult Schwann cells infected with Mycobacterium leprae (the causative agent of leprosy)...... more....
RayBiotech, Inc. Executes Neuroscience Biomarker Master Services Agreement with Banner Sun Health Research Institute
January 31, 2013 - Norcross, GA
RayBiotech, Inc. announced today that it has executed a master services agreement with Banner Sun Health Research Institute (BSHRI) of Sun City, Arizona. Under the terms of the agreement, RayBiotech will provide priority services for the biochemical analysis of disease markers in biological samples. A particular focus of the pact will be on the characterization of key biomarkers for the study of neurodegenerative disorders such as Alzheimer's and Parkinson's diseases...... more....
July 1, 2013 - Norcross, GA
RayBiotech, Inc. announced today their sponsorship of a new funding opportunity for biomedical science researchers, a program called the "2013 RayBiotech Innovative Research Grant." Terms of the grant program state that eligible topics include studies on model systems for biological processes and disease, biomarker discovery and validation, biomedical and veterinary sciences, biotechnology and biological sciences (including biochemistry, cell biology, genetics, physiology, plant sciences, environmental sciences, nutrition and food sciences). The highest scoring applicants will receive up to $15,000 worth of RayBiotech products, which include antibody arrays, ELISA kits, reagents, and custom services. The grant program is open to researchers worldwide... more....
RayBiotech, Inc. and Abeome Corporation Announce an Agreement Related to Novel Research Products for Ovarian Cancer
November 1, 2012 - Norcross, GA
RayBiotech, Inc. and Abeome Corporation today announced that the companies have entered into a collaboration whereby Abeome will provide over 300 novel monoclonal antibodies recognizing human ovarian cancer for use in the development of RayBiotech's antibody-related portfolio of products. These antibodies recognize ovarian cancer but not normal ovary tissue. Financial terms were not disclosed...... more....
October 17, 2012 - Norcross, GA
RayBiotech, Inc. ("RBI") today announced that it is convening a two-day Global Distributor Conference at its headquarters in suburban Atlanta, Georgia. Distributors representing over thirty-five international countries will participate in this conference where RBI management will address expanded strategic growth objectives for the next five years. In addition, the conference will focus on new product launches, new service offerings and overall technical training related to the RayBiotech portfolio of high-value research products and services. Included will be recognition of those distributors who have excelled in their development of the RayBiotech business..... more....
September 26, 2012 - Norcross, GA
RayBiotech, Inc. today announced that it has executed a comprehensive license agreement with Emory University. Under the terms of the agreement, RayBiotech will have access to a broad portfolio of antibody-related reagents and technologies developed by Emory researchers. These reagents and technologies will enable RayBiotech to rapidly expand its antibody-based products and services platforms..... more....
RayBiotech, Inc. Achieves Both GMP- and GLP-Compliance and Announces New Dedicated Services Laboratory
September 5, 2012 - Norcross, GA
RayBiotech, Inc. today announced that the company has established formal compliance in both Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP). Particular product lines now manufactured under GMP status include Quantibody, G-, C- and L-Series antibody arrays as well as all ELISA-related products, but the compliance under GMP guidelines will apply to all products developed, manufactured and sold by the company. GLP-compliance will apply to the performance of all biological sample analysis services. Related to this, RayBiotech also announced the recent construction and launch of a new GLP-compliant laboratory that will be dedicated exclusively to the implementation of ELISA and antibody array biomarker.... more....
Cytokine Antibody Array Assays Developed by RayBiotech, Inc. Used to Identify Key Cancer Cell Chemoresistance Pathway
August 20, 2012 - Norcross, GA
RayBiotech, Inc. announced today that several antibody-based biomarker screening assays developed by the company were utilized to identify a critical pathway involved in chemotherapeutic resistance acquired by melanoma cancer cells. Specifically, the RayBio® G-Series 4000 and the RayBio® L-Series 507 cytokine antibody arrays allowed the characterization of a specific pathway associated with the cancer cells’ ability to develop resistance to chemotherapeutic agents. Utilizing RayBiotech’s antibody arrays, the authors discerned that the microenvironment of a melanoma tumor plays a crucial role in modulating resistance to certain cancer drugs.... more....
July 11, 2012 - Norcross, GA
RayBiotech, Inc. today announced the formal launch of a peptoid drug candidate & diagnostic ligand discovery service program. Peptoids, a chemically stable class of peptide mimetics, have been recently exploited as ligands to virtually any protein target including antibodies, cellular signaling molecules, or receptors. Aimed at the identification of novel ligands for client-driven drug targets, RayBiotech’s new service platform will involve multi-stage screening of targets against a complex combinatorial peptoid library, followed by peptoid sequence refinement and optimization. To enhance the customization of their service, RayBiotech will also offer... more....
June 18, 2012 - Norcross, GA
RayBiotech, Inc. and the combined genotyping core facility for Oslo University Hospital and the University of Oslo, located at the Institute for Cancer Research, announced the execution of an agreement to collaborate for the implementation of antibody-based sample analysis services. Under the terms of the agreement, the combined core facility will provide a comprehensive service utilizing RayBiotech’s proprietary antibody arrays for the high-throughput detection and analysis of protein biomarkers in biological samples. The service program will target academic and industrial research clients having a need for fully quantifiable biomarker analysis... more....
May 22, 2012 - Norcross, GA
RayBiotech, Inc. today announced that it has executed a master services agreement with a major West Coast-based biopharmaceutical company. Under the terms of the agreement, RayBiotech will provide custom services in the area of high-throughput preclinical research diagnostic testing. Specifically, RayBiotech will employ its antibody array diagnostics technologies to collect quantitative diagnostics information regarding key biochemical targets involved in human physiology and disease. Due to the sensitivity of the research, the partner company’s identity is not being disclosed... more....
April 17, 2012 - Norcross, GA
RayBiotech, Inc. today announced that it has formally launched a partnering program for select diagnostic core facilities at academic and government research institutes in the United States and Canada. Under the terms of the partnership program, core diagnostics facilities will be able to provide proprietary RayBiotech proteomic analysis services as a component of their current services offerings at no cost to the core facilities. These services will be provided to select cores which emphasize biomarker and proteomic analysis to their affiliated researchers... more....
April 10, 2012 - Norcross, GA
RayBiotech, Inc. today announced that it has entered into a co-marketing partnership with Innopsys of Carbonne, France to promote the sales of RayBiotech’s G-Series and Quantibody series of antibody arrays and array testing services with Innopsys’ Innoscan laser microarray scanning platforms. The terms of the partnership were not disclosed... more....
An Open Letter from RayBiotech’s President to Our Distributors
March 26, 2012 - NORCROSS, GA.
Dear RayBiotech Distributors:
First, let me thank each of you for working with us as a RayBiotech distributor. We sincerely appreciate
your efforts to promote our products and services worldwide, focusing on achieving a mutually
beneficial growth and development of our products in your markets. Second, let me outline a few
actions that we have recently taken, intended to positively impact your efforts and ultimately your
November 07, 2011 - NORCROSS, GA.
RayBiotech, Inc., today announced that it has engaged recognized industry expert, David A. Dodd of RiversEdge BioVentures LLC to work with the Company in the areas of Business Development and Strategic Growth Opportunities. This will include the evaluation of enhanced commercial growth opportunities, business development and options for further portfolio expansion. Mr. Dodd will work directly with the team at RayBiotech, while focusing on opportunities to further expand the current highly successful growth and development of the Company... more....
July 19, 2011 - NORCROSS, GA.
RayBiotech, Inc., has just launched a Risk-Free Trial on its ELISA kits, stipulating that if a researcher is unsatisfied with the performance of any RayBio® ELISA, EIA, or phosphorylation ELISA, they can receive a full product refund or credit.... more....
Dec 02, 2010 - NORCROSS, GA.
RayBiotech, Inc., announced today it will renew its Biomarker Discovery Pilot Grant program for 2011 and will accept applications for restricted pilot grants of $5,000 to $20,000 worth of RayBiotech products and/or services beginning in early 2011...more....
October 28, 2010 - NORCROSS, GA.
RayBiotech, Inc., the Protein Array Pioneer Company, today announced the release of several antibody array products that can detect up to 34 proteins related to the recently discovered Th17 lineage of immune cells...more....
RayBiotech, Inc. Awarded NIH Grant for Endometriosis Research
October 20, 2010 - NORCROSS, GA.
RayBiotech, Inc., a leading developer and supplier of multiplex protein and antibody arrays, was recently awarded a federally funded research grant to develop a cost-effective diagnostic test for endometriosis, an enigmatic reproductive disease in women. Their grant is funded by the Small Business Technology Transfer (STTR), a competitive grant program administered by the National Institutes of Health (NIH)...
RayBiotech, Inc. and Gentel Partner to Offer Comprehensive Selection of Arrays on APiX Chromogenic Detection Platform
October 4, 2010 - NORCROSS, GA.
RayBiotech, Inc., a pioneer and leader in protein and antibody array technologies, and Gentel Biosciences, a leader in proteomics profiling tools, jointly announce today their partnership to develop and market RayBiotech's vast collection of antibody array products covering a wide variety of cytokines and other proteins for use with Gentel's APiXâ„¢ chromogenic detection platform...
RayBiotech, Inc. Announces Biomarker Grant Awardees
May 05, 2010
RayBiotech announced the recipients of its Biomarker Discovery Grants. By sponsoring these awards, RayBiotech intends to demonstrate that any researcher with a modest research budget can discover disease-related biomarkers using its antibody arrays...
RayBiotech, Inc. Role of YAP in Cancer Revealed Using EGFR Phosphorylation Array
January 22, 2010 - NORCROSS, GA.
Two RayBio® antibody arrays, the Human Growth Factor Array I and the Human EGFR Phosphorylation Array I, were instrumental in the discovery of amphiregulin (AREG) as a key effector of transcription factor YAP in breast epithelial cells.
RayBiotech, Inc. Introduces Multiplex ELISA Detecting 200 Human Proteins
December 10, 2009 - NORCROSS, GA.
RayBiotech, the Protein Array Pioneer Company, has just introduced the Quantibody® Human Cytokine Array 4000 (or Human Q4000, catalog number QAH-CAA-4000), which can quantitatively detect expression of 200 different proteins in a single experiment.
RayBiotech, Inc. announced the establishment of Biomarker Discovery Pilot Grant program
September 24, 2009 - NORCROSS, GA.
RayBiotech today announced the establishment of its Biomarker Discovery Pilot Grant program. RayBiotech will accept applications for pilot grants beginning today through January 31, 2010. Winning applicants will be eligible for restricted grants of RayBiotech Products worth $10,000 to $20,000 to conduct their proposed protein biomarker research, which would potentially be sufficient to generate preliminary data for additional grant funding.
RayBiotech, Inc. Now Offers Nearly 500 Different RayBio® ELISA Kits
June 1, 2009 - NORCROSS, GA.
RayBiotech Now Offers Nearly 500 ELISA Kits:
RayBiotech, Inc. and Satoris announce collaboration to develop and commercialize Early Alzheimer's Test
April 16, 2009 - NORCROSS, GA., and REDWOOD CITY, CALIF.
RayBiotech and Satoris Annouce Collaboration to Develop and Commercialize Early Alzheimer's Test: RayBiotech, Inc., a leading developer and supplier of multiplex protein detection arrays and array-based test kits, and Satoris, Inc., a molecular diagnostics company focused on developing blood-based tests for Alzheimer's disease, and, announced that they intend to cooperate in developing and commercializing an Alzheimer?s detection blood test based on Satoris? proprietary plasma biomarkers.
RayBiotech, Inc. Introduces Multiplex ELISA Quantitatively Detecting 160 Human Proteins
April 8, 2009 - NORCROSS, GA.
RayBiotech Introduces Multiplex ELISA Quantitatively Detecting 160 Human Proteins
RayBiotech, Inc. Introduces Human Apoptosis Antibody Array to Detect 43 Different Apoptotic Proteins in one sample
April 8, 2009 - NORCROSS, GA.
RayBiotech Introduces Human Apoptosis Antibody Array to Detect 43 Different Apoptotic Proteins in one sample.